Alnylam Pharmaceuticals (ALNY) Trading Up 0%
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) was up 0% on Monday . The stock traded as high as $143.83 and last traded at $142.04. Approximately 1,332,439 shares were traded during trading, an increase of 64% from the average daily volume of 812,293 shares. The stock had previously closed at $142.04.
Several equities research analysts have recently weighed in on ALNY shares. Goldman Sachs Group upgraded shares of Alnylam Pharmaceuticals from a “buy” rating to a “conviction-buy” rating in a research report on Friday, December 15th. Piper Jaffray Companies reiterated a “buy” rating and set a $182.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Friday, November 17th. Leerink Swann increased their price objective on shares of Alnylam Pharmaceuticals from $132.00 to $135.00 and gave the stock a “market perform” rating in a research report on Thursday, January 25th. BidaskClub cut shares of Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, December 7th. Finally, B. Riley reiterated a “buy” rating and set a $220.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Monday, December 11th. Three analysts have rated the stock with a sell rating, seven have assigned a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $126.89.
The firm has a market capitalization of $14,180.00, a P/E ratio of -26.65 and a beta of 2.67. The company has a debt-to-equity ratio of 0.02, a quick ratio of 12.23 and a current ratio of 12.23.
In related news, VP Michael Mason sold 36,745 shares of the firm’s stock in a transaction dated Thursday, January 4th. The shares were sold at an average price of $131.59, for a total transaction of $4,835,274.55. Following the transaction, the vice president now directly owns 6,352 shares of the company’s stock, valued at $835,859.68. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Philip A. Sharp sold 15,000 shares of the firm’s stock in a transaction dated Friday, March 9th. The shares were sold at an average price of $129.00, for a total transaction of $1,935,000.00. Following the transaction, the director now directly owns 155,795 shares in the company, valued at $20,097,555. The disclosure for this sale can be found here. Insiders have sold 57,994 shares of company stock worth $7,527,653 over the last three months. 4.30% of the stock is owned by insiders.
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Strs Ohio bought a new position in shares of Alnylam Pharmaceuticals during the fourth quarter valued at about $141,000. CENTRAL TRUST Co increased its holdings in Alnylam Pharmaceuticals by 746.3% during the fourth quarter. CENTRAL TRUST Co now owns 1,134 shares of the biopharmaceutical company’s stock worth $144,000 after buying an additional 1,000 shares during the last quarter. Livforsakringsbolaget Skandia Omsesidigt purchased a new stake in Alnylam Pharmaceuticals during the fourth quarter worth about $165,000. Segall Bryant & Hamill LLC purchased a new stake in Alnylam Pharmaceuticals during the third quarter worth about $235,000. Finally, American International Group Inc. purchased a new stake in Alnylam Pharmaceuticals during the fourth quarter worth about $255,000. 92.44% of the stock is currently owned by institutional investors.
COPYRIGHT VIOLATION NOTICE: “Alnylam Pharmaceuticals (ALNY) Trading Up 0%” was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this news story on another domain, it was illegally stolen and reposted in violation of international trademark and copyright legislation. The original version of this news story can be read at https://www.thecerbatgem.com/2018/03/14/alnylam-pharmaceuticals-alny-trading-up-0.html.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.